IONS Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
267.9M
+8.9%
246.1M
+21.0%
203.3M
+29.7%
156.7M
-65.3%
452.0M
Cost of Revenue
2.7M
-8.2%
3.0M
-62.5%
8.0M
+240.3%
2.3M
-43.7%
4.2M
Gross Profit
265.2M
+9.1%
243.1M
+24.4%
195.4M
+26.6%
154.4M
-65.5%
447.9M
Operating Expenses
367.5M
+1.9%
360.5M
-12.0%
409.8M
+30.3%
314.6M
+2.1%
308.1M
R&D
217.1M
+3.3%
210.2M
-24.8%
279.6M
+28.4%
217.8M
+0.1%
217.5M
SG&A
150.4M
+0.0%
150.4M
+15.5%
130.2M
+34.5%
96.8M
+6.8%
90.6M
Operating Income
-102293000
+12.9%
-117424000
+45.2%
-214459000
-33.9%
-160182000
-214.6%
139.8M
EBITDA
-98160000
+13.5%
-113462000
+46.7%
-213001000
-35.4%
-157306000
-210.3%
142.7M
Net Income
-114646000
-23.9%
-92528000
+59.7%
-229394000
-78.4%
-128606000
-204.1%
123.6M
EPS (Basic)
$-0.69
-23.2%
$-0.56
+60.3%
$-1.41
-76.2%
$-0.80
-202.6%
$0.78
EPS (Diluted)
$-0.69
-23.2%
$-0.56
+66.1%
$-1.65
-106.2%
$-0.80
-214.3%
$0.70
Shares (Diluted)
165.4M
+0.3%
164.9M
+18.4%
139.2M
-12.9%
159.8M
-12.4%
182.3M
Ionis Pharmaceuticals (IONS) โ€” Financials